Bioorganic and Medicinal Chemistry p. 5852 - 5869 (2018)
Update date:2022-08-15
Topics:
Zhou, Qingqing
Reekie, Tristan A.
Abbassi, Ramzi H.
Indurthi Venkata, Dinesh
Font, Josep S.
Ryan, Renae M.
Munoz, Lenka
Kassiou, Michael
Dual-specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is a dual-specificity protein kinase that catalyses phosphorylation and autophosphorylation. Higher DYRK1A expression correlates with cancer, in particular glioblastoma present within the brain. We report here the synthesis and biological evaluation of new heterocyclic diphenolic derivatives designed as novel DYRK1A inhibitors. The generation of these heterocycles such as benzimidazole, imidazole, naphthyridine, pyrazole-pyridines, bipyridine, and triazolopyrazines was made based on the structural modification of the lead DANDY and tested for their ability to inhibit DYRK1A. None of these derivatives showed significant DYRK1A inhibition but provide valuable knowledge around the importance of the 7-azaindole moiety. These data will be of use for developing further structure-activity relationship studies to improve the selective inhibition of DYRK1A.
View MoreJi'an Hairui Natural Plant Co. Ltd.
Contact:0796-8105528
Address:Meilin industry park, Qingyuan district Ji'an City, Jiangxi Province
Nanjing distinctions Medical Technology Co., Ltd.
Contact:+86-15996203785 13914714059
Address:nanjing,jiangsu , China
Chengda Pharmaceuticals Co., Ltd.
Contact:+86-573-84601188
Address:hengshan Road 5# in Jiashan, zhejiang
Contact:86-571-61063068
Address:LINAN
SJZ Chenghui Chemical Co., Ltd.
Contact:86-311-87713916
Address:no.368 youyi north avenue
Doi:10.1016/S0040-4020(01)83106-9
(1969)Doi:10.1515/znb-2001-0307
(2001)Doi:10.3762/bjoc.14.72
(2018)Doi:10.1246/cl.1984.29
(1984)Doi:10.1039/d0md00208a
(2020)Doi:10.1016/j.bmc.2019.115090
(2019)